New York, NY -- (SBWIRE) -- 01/09/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: EarthLink, Inc (NASDAQ:ELNK), Globalstar, Inc (OTCMKTS:GSAT), Hemispherx BioPharma, Inc (NYSEMKT:HEB), Oclaro, Inc (NASDAQ:OCLR)
EarthLink, Inc (NASDAQ:ELNK) showed a volume of 1.38 million shares by the end of last trade whereas the average volume of the stock remained 967,903 shares. The stock opened the session at $5.59 but then moved to $5.43. At that price, the stock showed a negative performance of -2.69%. EarthLink, Inc. (EarthLink), is a network, communications and information technology (IT) services provider to business and residential customers in the United States. The Company operates in two segments: Business Services and Consumer Services. EarthLink’s Business Services segment provides a range of data, voice, managed IT and equipment services to business customers. Its Consumer Services segment provides nationwide Internet access and related value-added services to residential customers. EarthLink operates a network, including approximately 28,800 route miles of fiber,
Will ELNK Get Buyers Even After The Recent Rally? Find Out Here
Globalstar, Inc (OTCMKTS:GSAT) opened the session at $1.73 and closed the session at $1.72. The stock showed a negative performance of -0.58% in previous trading session. Traded with volume of 1.38 million shares in the prior session and the average volume of the stock remained 4.11 million shares. Globalstar, Inc. (Globalstar) is a provider of mobile voice and data communications services globally via satellite. Globalstar’s satellite communications business, by providing critical mobile communications to the Company's subscribers, serves principally recreation and personal; government; public safety and disaster relief; oil and gas; maritime and fishing; natural resources, mining and forestry; construction; utilities and transportation. As of March 2, 2012, the Company used 36 in-orbit satellites providing service and 24 active ground stations, which it refers to as gateways, to offer voice and data communication services.
Has GSAT Found The Bottom And Ready To Gain Momentum? Find Out Here
Hemispherx BioPharma, Inc (NYSEMKT:HEB) opened the session at $0.31 and closed the session at $00.291. The stock showed a negative performance of -5.15% in previous trading session. Traded with volume of 1.37 million shares in the prior session and the average volume of the stock remained 2.04 million shares. The beta of the stock remained 1.77. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.
Why Should Investors Buy HEB After the Recent Fall? Just Go Here and Find Out
Oclaro, Inc (NASDAQ:OCLR) the stock advanced 3.32% and finished the session at $2.80. Traded with volume of 1.36 million shares in the prior session and the average volume of the stock remained 953,931.00 shares. The beta of the stock remained 3.84. Oclaro, Inc. is a provider of optical communications and laser components, modules and subsystems for a range of markets, including telecommunications (telecom), industrial, scientific, consumer electronics and medical. The Company’s product offerings include tunable laser, lithium niobate external modulators, pump laser chips, thin film filters, and amplifiers. The Company is a supplier of optical network technology to telecom equipment companies worldwide.
Will OCLR Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)